

Can nuclear theory help find an anti-viral drug for COVID-19?

Pietro Faccioli




UNIVERSITÀ DEGLI STUDI
DI TRENTO


Dipartimento di Fisica



Trento Institute for
Fundamental Physics
and Applications






A LONG JOURNEY




Chalkboard with mathematical equations:

$$\mathcal{L} = \frac{1}{4\pi^2} G_{\mu\nu}^a G_{\mu\nu}^a + \sum_f \bar{\psi}_f (i\gamma^\mu \partial_\mu + m_f) \psi_f$$

where $G_{\mu\nu}^a = \partial_\mu A_\nu^a - \partial_\nu A_\mu^a + g_s f_{abc} A_\mu^b A_\nu^c$
and $D_\mu = \partial_\mu + i g_s A_\mu^a T_a$
That's it!





REDUCTIONIST'S APPROACH TO MOLECULAR BIOLOGY



Challenge:

Integrate $\sim 10^6$ coupled
Newton-type equations
looking for **extremely
rare events**

RARE EVENT PROBLEMS




MD YIELDS CORRECT PROTEIN NATIVE STATES



Anton supercomputer
(DES Research)



MD



Atomic-Level Characterization of the Structural Dynamics of Proteins
David E. Shaw, *et al.*
Science **330**, 341 (2010);
DOI: 10.1126/science.1187409

How Fast-Folding Proteins Fold

Kresten Lindorff-Larsen,^{1*}† Stefano Piana,^{1*}† Ron O. Dror,¹ David E. Shaw^{1,2†}

ZOOLOGY OF ENHANCED SAMPLING METHODS

Markov State Models, Milestoning, Transition Path Sampling, Transition Interface Sampling, Forward Flux Sampling, Temperature Accelerated Molecular Dynamics, Metadynamics, Umbrella Sampling, Blue Moon Sampling, String Method, Stochastic Difference, ... [and counting]


They are **all too computationally demanding** for many biologically relevant problems.

A LONG JOURNEY

$$\mathcal{L} = \frac{1}{2} G_{\mu\nu}^a G_{\mu\nu}^a + \sum_f \bar{\psi}_f (i \not{\partial} - m_f) \psi_f$$

where $G_{\mu\nu}^a = \partial_\mu A_\nu^a - \partial_\nu A_\mu^a + g_s f_{abc} A_\mu^b A_\nu^c$
and $D_\mu = \partial_\mu + i g_s A_\mu^a$


That's it!



A USEFUL ANALOGY


Thermal activation

($\beta = (K_B T)^{-1}$)




$$P(x_f, t | x_i) = \int_{x_i}^{x_f} \mathcal{D}q e^{-\frac{\beta}{4M\gamma} \int_0^t d\tau (M\ddot{q} + M\gamma\dot{q} + \nabla U(q))^2}$$

Quantum tunneling



$$K_E(x_f, t | x_i) = \int_{x_i}^{x_f} \mathcal{D}q e^{-\frac{1}{\hbar} \int_0^t d\tau (\frac{M}{2} \dot{q}^2 + U(q))}$$

ADVANTAGES



$$t_{TPT} \sim \tau_0 \log \left[\log \left(\frac{t_{MFPT}}{\tau_0} \right) \right]$$

VARIATIONAL APPROACHES TO TRANSITION PATH SAMPLING

Dominant Reaction Pathways

PRL 97, 108101 (2006)

PHYSICAL REVIEW LETTERS

week ending
8 SEPTEMBER 2006

Dominant Pathways in Protein Folding

(2005)

PRL 99, 118102 (2007)

PHYSICAL REVIEW LETTERS

week ending
14 SEPTEMBER 2007

Quantitative Protein Dynamics from Dominant Folding Pathways

(2006)

Dominant folding pathways of a WW domain

Silvio a Beccara^{ab}, Tatjana Škrbić^{ac}, Roberto Covino^{ab}, and Pietro Faccioli^{ab,1}

^aDipartimento di Fisica, Università degli Studi di Trento, Via Sommarive 14, I-38123 Povo (Trento), Italy; ^bINFN Istituto Nazionale di Fisica Nucleare (National Institute for Nuclear Physics), Gruppo Collegato di Trento, Via Sommarive 14, I-38123 Povo (Trento) Italy; and ^cEuropean Centre for Theoretical Studies in Nuclear Physics and Related Areas, Strada delle Tabarelle 286, I-38123 Villazzano (Trento), Italy

Edited by William A. Eaton, National Institutes of Health -NIDDK, Bethesda, MD, and approved December 19, 2011 (received for review July 27, 2011)

(2012)

Bias Functional Approach

PRL 114, 098103 (2015)

PHYSICAL REVIEW LETTERS

week ending
6 MARCH 2015

Variational Scheme to Compute Protein Reaction Pathways Using Atomistic Force Fields with Explicit Solvent

(2015)

Self Consistent Path Sampling



THE JOURNAL OF CHEMICAL PHYSICS 147, 064108 (2017)

Self-consistent calculation of protein folding pathways

S. Orioli, S. a Beccara, and P. Faccioli^{a)}

(2017)


HUGE COMPUTATIONAL GAIN





Using top all-purpose supercomputers

Using top special-purpose supercomputer

VALIDATING SCPS AGAINST MD





VENTURING INTO THE BIO-ZONE



A LONG JOURNEY


$$\mathcal{L} = \frac{1}{4g^2} G_{\mu\nu}^a G_{\mu\nu}^a + \sum_f \bar{\psi}_f (i \not{D} - m_f) \psi_f$$

where $G_{\mu\nu}^a = \partial_\mu A_\nu^a - \partial_\nu A_\mu^a + g f^{abc} A_\mu^b A_\nu^c$
and $D_\mu = \partial_\mu + i g A_\mu^a T^a$
That's it!



VALIDATION AGAINST EXPERIMENT


Experiment



Challenge:

Most available techniques provide only indirect probes, we seek for **direct validation**

TIME-DEPENDENT LINEAR SPECTROSCOPY



--- Ground state
→ One exciton

Challenge:

Need a theory for **non-equilibrium dynamics** of **quantum** electronic excitations in conformationally evolving proteins

MOLECULAR QUANTUM FIELD THEORY*

$$Z = \int \mathcal{D}\psi \mathcal{D}\bar{\psi} \int \mathcal{D}q e^{-S_{MQFT}[\psi, \bar{\psi}, q]}$$

$$S_{MQFT}[q, \psi, \bar{\psi}] = S_{OM}[q] + S_S[\psi, \bar{\psi}] + S_{int}[q, \psi, \bar{\psi}]$$


$$S_{OM}[q] = \int_0^t d\tau \frac{\beta}{4M\gamma} (M\ddot{q} + M\gamma\dot{q} + \nabla U(q))^2$$

$$S_S[\psi, \bar{\psi}] = \sum_{n,m} \int_0^t d\tau \bar{\psi}_n(\tau) (i\hbar\partial_t - h_{nm}^0) \psi_m(\tau)$$

$$S_{int}[q, \psi, \bar{\psi}] = \sum_{nm} \sum_i \int_0^t d\tau f_{nm}^i \bar{\psi}_n \psi_m \delta q_i$$


SOLVING MQFT: AN ARSENAL OF METHODS

Perturbation Theory




PRB 2012, PRB 2013, PRB 2016

Quantum MC
(for real time)



PRB 2016


Renorm. Group &
Eff. Field Theory




PRB 2013, JCP 2016

EXAMPLES OF DIRECT COMPARISON WITH EXPERIMENTS

Time resolved near UV CD*



Linear absorption spectrum



Microscopic Calculation of Absorption Spectra of Macromolecules: an Analytic Approach

Matteo Carli

Physics Department of Trento University, Via Sommarive 14, Povo (Trento), 38123, Italy and
Scuola Internazionale Superiore di Studi Avanzati (SISSA), via Bonomea 265, Trieste 34136, Italy.

Michele Turelli and Pietro Faccioli*

Physics Department of Trento University, Via Sommarive 14, Povo (Trento), 38123, Italy and
Trento Institute for Fundamental Physics and Applications (INFN-TIFPA), Via Sommarive 23, Povo (Trento), 38123, Italy

J|A|C|S
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Cite This: *J. Am. Chem. Soc.* 2018, 140, 3674–3682

pubs

Atomic Detail of Protein Folding Revealed by an Ab Initio Reappraisal of Circular Dichroism

Alan Ianeselli,[†] Simone Orioli,^{‡,||} Giovanni Spagnoli,[†] Pietro Faccioli,^{*,‡,||} Lorenzo Cupellini,[§] Sandro Jurinovich,[§] and Benedetta Mennucci^{*,§}

* with B. Mennucci's Lab (U. Pisa)

EXPLORING BIOLOGICAL PROCESSES


Serpin latency transition at atomic resolution

Giorgia Cazzoli^{1,2}, Fang Wang³, Silvio a Beccara^{4,5}, Anne Gershenson⁶, Pietro Faccioli^{2,3,1}, and Patrick L. Wintrod^{6,1}

¹Dipartimento di Fisica, Università degli Studi di Trento, 38100 Povo (Trento), Italy; ²Trento Institute for Fundamental Physics and Applications, 38123 Povo (Trento), Italy; ³Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201; ⁴Interdisciplinary Laboratory for Computational Science, Fondazione Bruno Kessler, 38123 Povo (Trento), Italy; and ⁵Department of Biochemistry and Molecular Biology, University of Massachusetts Amherst, Amherst, MA 01003

Edited by David E. Shaw, D. E. Shaw Research, New York, NY, and approved September 12, 2014 (received for review April 24, 2014)

Protease inhibition by serpins requires a large conformational transition from an active, metastable state to an inactive, stable state for polypeptide chains consisting of nearly 100 amino acids (6), which are considerably smaller than PAI-1. Additionally, the




Biophysical Journal
Article

Biophysical Society

All-Atom Simulations Reveal How Single-Point Mutations Promote Serpin Misfolding

Fang Wang,¹ Simone Orioli,^{2,3} Alan Ianeselli,^{2,3} Giovanni Spagnoli,^{2,3} Silvio a Beccara,^{2,3} Anne Gershenson,^{4,*} Pietro Faccioli,^{2,3,*} and Patrick L. Wintrod^{1,*}




PLOS PATHOGENS

RESEARCH ARTICLE

Full atomistic model of prion structure and conversion

Giovanni Spagnoli^{1,*}, Marta Rigoli^{1,2}, Simone Orioli^{2,3}, Alejandro M. Sevillano⁴, Pietro Faccioli^{2,3}, Holger Wille⁵, Emiliano Biasini^{1,*}, Jesús R. Requena^{6,*}



All-Atom Simulation of the HET-s Prion Replication

Luca Terruzzi^{1,2,*}, Giovanni Spagnoli^{2,3,*}, Alberto Boldrini^{1,2}, Jesús R. Requena⁴, Emiliano Biasini^{2,3} and Pietro Faccioli^{5,6}





Teaming up with
E. Biasini's lab (DICIBIO)

A LONG JOURNEY

$$\mathcal{L} = \frac{1}{4g^2} G_{\mu\nu}^a G^{\mu\nu a} + \sum_f \bar{q}_f (i \not{\partial} + m_f) q_f$$

where $G_{\mu\nu}^a = \partial_\mu A_\nu^a - \partial_\nu A_\mu^a + g_s f^{abc} A_\mu^b A_\nu^c$
and $D_\mu = \partial_\mu + i g_s A_\mu^a T^a$
That's it!



ROLE OF PROTEIN INACTIVATION


MOST OF BIOLOGICAL FUNCTIONS IN CELLS ARE CARRIED
OUT BY **PROTEINS**





MOST OF MEDICINAL CHEMISTRY IS BASED ON
INHIBITING BIOLOGICAL FUNCTIONS OF PROTEINS

PHARMACOLOGICAL PROTEIN INACTIVATION BY FOLDING INTERMEDIATE TARGETING

patent file # 102018000007535 (with E. Biasini)







PHARMACOLOGICAL PROTEIN INACTIVATION BY FOLDING INTERMEDIATE TARGETING



A FIRST VALIDATION

Inactivation of Cellular Prion protein






PHARMACOLOGICAL PROTEIN INACTIVATION BY TARGETING FOLDING INTERMEDIATES

● Giovanni Spagnoli, Tania Massignan, Andrea Astolfi, Silvia Biggi, Paolo Brunelli, Michela Libergoli, Alan Ianeselli, Simone Orioli, Alberto Boldrini, Luca Terruzzi, Giulia Maietta, Marta Rigoli, Nuria Lopez Lorenzo, Leticia C. Fernandez, Laura Tosatto, Luise Linsenmeier, Beatrice Vignoli, Gianluca Petris, Dino Gasparotto, Maria Pennuto, Graziano Guella, Marco Canossa, Hermann Clemens Altmepfen, Graziano Lolli, Stefano Biressi, Manuel Martin Pastor, Jesús R. Requena, Ines Mancini, Maria Letizia Barreca, Pietro Faccioli, ● Emiliano Biasini

doi: <https://doi.org/10.1101/2020.03.31.018069>

PPI-FIT PIPELINE



Computing the folding pathways
characterizing
intermediate states

In-silico virtual
screening on folding
intermediate targets

in-vitro evaluation
of the effect of the
selected compounds
on protein expression

Refinement
SAR,
pharmaco-kinetics,
.....

FINAL GOAL

*Preclinical
and clinical trials*



Joining Forces against COVID-19

Maria Letizia Barreca




UNIVERSITÀ DEGLI STUDI DI PERUGIA



Emiliano Biasini




UNIVERSITÀ DI TRENTO

FONDAZIONE **telethon**



Pietro Faccioli




UNIVERSITÀ DI TRENTO

TIFPA



Graziano Lolli




UNIVERSITÀ DI TRENTO




INFN

Istituto Nazionale di Fisica Nucleare

30.000 cores in 8 data centers



Lidia Pieri




Giovanni Spagnoli




Alberto Boldrini

Tania Massignan






Luca Terruzzi




Andrea Astolfi




SARS-CoV-2 Replication





Goals:

Repurposing of approved drugs!
Looking for suppressors of ACE2
expression levels

Figure taken from:

<https://theconversation.com/where-are-we-at-with-developing-a-vaccine-for-coronavirus-134784>

PPI-FIT ON ACE2





Out of 9000 candidates, we found 35 molecules binding in-silico the intermediate. Validation experiments on cellular bio-assays are ongoing.

BREAKING NEWS!! (17/05/2020)

So far, Sibylla Biotech has tested 14 virtual hits


ONE DISPLAYS A **PROMINENT EFFECT** WITH CLEAR **DOSE-RESPONSE** RELATIONSHIP AND VERY **LOW TOXICITY**



PPI-FIT Pipeline



ACE-2 folding pathway reconstruction and intermediate state characterization



in-silico hit compounds identification. Virtual screening on FDA approved or investigational drugs




in-vitro evaluation of the effect of the selected compounds on ACE2 expression (degradation wanted)



in-vitro evaluation of the effect of compounds lowering the expression of ACE2 on SARS-COV-2 virus replication

FINAL GOAL

Preclinical and clinical trials



MAIN TAKE-HOME MESSAGES

Fundamental research matters!


The usefulness of **theoretical physics** extends beyond its natural cultural perimeter

Major research infrastructures for fundamental research can be **re-purposed**

Technological transfer can boost research and help advance Science

People

**Maria Letizia
Barreca PhD**



**Emiliano Biasini
PhD**



**Pietro Faccioli
PhD**



**Graziano Lolli
PhD**



**Lidia Pieri
PhD**



Founder - CEO



**Giovanni
Spagnoli**



Founder
Chief Scientist



Alberto Boldrini



Staff
(Computational)



**Tania
Massignan PhD**



Staff (Wet Lab)



Luca Terruzzi



Staff
(Computational)



**Andrea Astolfi
PhD**



Consultant
Medicinal Chemist



Acknowledgments




Trento Institute for
Fundamental Physics
and Applications



Italy:

Trento: *E. Biasini*, *A. Ianeselli* (2014-2017), *G. Spagnoli* *S. A Beccara* (2009-2017), *S. Orioli* (2014-2018), *E. Schneider* (2012-2015), *M. Carli* (2017), *M. Turelli* (2018), *F. Mascherpa* (2014), *G. Garberoglio*, *F. Pederiva*, *M. Sega*, *R. Covino* (2012-2015),

Pisa: *B. Mennucci*, *L. Cupellini*, *S. Jurinovich*



Perugia: *L. Barreca*

SISSA: *C. Micheletti*, *A. Laio*

Europe:

U. Zurich: *B. Schuler*

U. Compostela: *J. Raquena*

CEA-Saclay: *H. Orland*

USA: U. Maryland: *P. Wintrode*

U. Mass.: *A. Gershenson*